Allergy & Immunology

Rocatinlimab, a novel therapy targeting the OX40 pathway, shows potential as an alternative treatment.

Current treatments focus on managing symptoms and include moisturisers, corticosteroids, and calcineurin inhibitors.

Recent studies demonstrate that IL-5 treatment substantially increases type I and III IFN production in mast cells exposed to respiratory viruses.

The Clinical Support Tool is a significant advancement, integrating clear clinical criteria and epinephrine treatment guidelines.

Given that 60% of asthma-related costs are attributed to severe, uncontrolled cases, the need for cost-effective treatment alternatives is crucial.

These findings indicate that omalizumab is a more effective and safer option than multi-allergen OIT for treating multi-food allergy.

Fine dust, a notable seasonal allergen, exacerbates allergic rhinitis symptoms and contributes to respiratory diseases.

Peanut oral immunotherapy using home-measured peanut butter significantly improves long-term desensitisation in children with high-threshold peanut allergy.